Akumentis Healthcare launches synthetic CBD for epilepsy – News Healthcare

Akumentis Healthcare Limited on Thursday announced that it has launched Clasepi. According to the company’s press statement, Clasepi, DCGI-approved prescription cannabidiol (CBD) is specifically formulated to address seizures linked with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in patients aged 1 year and older.

Clasepi marks a development as the first synthetic CBD product of its kind to be made available in India, it claimed. The product with THC content below 0.1%, stands out for its non-psychotropic nature.

Clinical studies have demonstrated Clasepi efficacy in reducing seizures, especially in cases where conventional antiseizure medications have proven ineffective.

“Patients grappling with a rare and severe form of epilepsy often endure a protracted journey to obtain an accurate diagnosis, tolerating nearly five years of uncontrolled seizures from the onset. In certain instances, individuals may enter adulthood without a precise diagnosis, despite wrestling with conditions like LGS, DS, or TSC.. We understand the immense physical and emotional toll that frequent seizures can have on patients and their families. This is the driving force behind
our commitment to developing novel solutions that effectively relieves the complexities of these disorders,” Kanishk Jain, Executive Director, Akumentis said.

According to the World Health Organisation (WHO), epilepsy constitutes a considerable portion of the global disease burden, affecting approximately 50 million people worldwide, with 20% of patients residing in India.

WHO asserts that up to 70% of individuals with epilepsy could achieve seizure freedom with the proper use of progressive anti seizure medicines. Beyond the
seizures themselves, pervasive myths and discrimination surrounding epilepsy create additional hurdles for affected individuals and their families. In India, a sizable number of patients suffers from Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) for whom doctors will find clasepi as a new armamentarium in epilepsy therapy protocol.

Clasepi comes with important usage considerations; it is not recommended for individuals allergic to cannabidiol or any of its ingredients. Akumentis stresses the significance of adhering to healthcare providers’ prescription guidance for optimal use and safe consumption, it added.